Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.48 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153677 | 0.87 | APP (0.50) | TSHRALDH1A1 | |
| SCHEMBL4871795 | 0.86 | MAPK1 (0.45) | MAPK1TSHRALOX15 | |
| SCHEMBL4866714 | 0.83 | RBP4 (0.36) | CYP2C19MAPK1MEN1KMT2AUSP2 | |
| SCHEMBL6154584 | 0.81 | MEN1 (0.51) | CYP2C19MEN1KMT2A | |
| SCHEMBL6153877 | 0.78 | KDM1A (0.41) | CYP3A4CYP2C19MAPK1TSHR | |
| SCHEMBL7379940 | 0.78 | SIGMAR1 (0.41) | MAPK1 | |
| SCHEMBL9963284 | 0.73 | CYP2D6 (0.46) | CYP2D6 | |
| SCHEMBL6155020 | 0.72 | AVPR1A (0.51) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL6097273 | 0.71 | NOTUM (0.58) | CYP3A4CYP2C19MAPK1MEN1KMT2A | |
| SCHEMBL25345704 | 0.70 | CYP3A4 (0.49) | CYP3A4CYP2C19MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209262-A1 | Process for producing optically active sulfoxide | SANKYO COMPANY, LIMITED (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1557420-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE | Sankyo Company, Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209262-A1 | Process for producing optically active sulfoxide | TST, TMT1A, PPOX | CYP3A4 185/4885CYP2C19 967/4885MAPK1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.